Login to Your Account



Mast Flags Offering's $22.9M for Sickle Cell Phase III Trial

By Randy Osborne
Staff Writer

Friday, June 14, 2013
Mast Therapeutics Inc.'s $22.9 million from a public offering will fund the second Phase III trial with the sickle cell disease candidate MST-188, a purified form of a nonionic, triblock copolymer (poloxamer 188) that was first developed for the treatment of heart attacks.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription